View Future GrowthBioSyent 과거 순이익 실적과거 기준 점검 5/6BioSyent은 연평균 12.9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 9.4% 증가했습니다. 매출은 연평균 11.7%의 비율로 증가했습니다. BioSyent의 자기자본이익률은 20.1%이고 순이익률은 19.7%입니다.핵심 정보12.88%순이익 성장률15.71%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률11.66%자기자본이익률20.09%순이익률19.65%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트공시 • May 08BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026공시 • Mar 13BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026공시 • Nov 14BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025공시 • Aug 15BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025공시 • May 09BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025공시 • Mar 07BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025모든 업데이트 보기Recent updates공시 • May 21BioSyent Inc. Announces Health Canada Approval of Thyconvi (Levothyroxine Oral Solution)BioSyent Inc. announced that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (TSH) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi in Canada. Thyconvi is an oral liquid dosage containing 20 micrograms (mcg) of levothyroxine sodium per millilitre (mL). Thyconvi is indicated for: Hypothyroidism - as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis. Pituitary Thyrotropin (TSH) Suppression - as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. Thyconvi is supplied in a package of two 75 mL bottles without the need for refrigeration. Thyconvi offers broad, convenient dose flexibility for patients who have challenges taking solid doses.공시 • May 16BioSyent Inc. Declares Second Quarter 2026 Dividend, Payable on June 15, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of CAD 0.055 per common share.공시 • May 08BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026공시 • Mar 13BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026공시 • Mar 03BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc from a group of shareholders for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow, and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Rory Cattanach of Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc. BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million on February 8, 2026. A cash payment of CAD 22.5 million, of which CAD 0.2 million will be satisfied by granting 12,666 Restricted Share Units to certain Oral Science employees, vesting on the second anniversary of the grant date. Also issued 234,192 common shares valued at CAD 3.0 million, of which 167,635 are under a two-year escrow and 66,557 are under a two-year lock-up, releasing 25% every six months. An additional CAD 2 million cash was paid at closing for excess working capital. The sellers may also receive a contingent earn-out in 2027 based on 2025–2026 performance and royalties until 2033 of up to CAD 6 million.공시 • Feb 17BioSyent Inc., Annual General Meeting, May 14, 2026BioSyent Inc., Annual General Meeting, May 14, 2026.공시 • Feb 09BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc.공시 • Jan 30BioSyent Inc. Declares Quarterly Dividend for the First Quarter of 2026, Payable on March 13, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share.공시 • Nov 22BioSyent Declares Fourth Quarter 2025 Dividend, Payable on December 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share.공시 • Nov 14BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025공시 • Aug 22BioSyent Inc. Declares Dividend for Third Quarter of 2025, Payable on September 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.05 per common share, payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of CAD 0.05 per common share.공시 • Aug 15BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025공시 • May 16BioSyent Inc. Declares Second Quarter 2025 Dividend, Payable on June 13, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.공시 • May 09BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025공시 • Mar 07BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025공시 • Mar 05BioSyent Inc., Annual General Meeting, May 15, 2025BioSyent Inc., Annual General Meeting, May 15, 2025. Location: ontario, mississauga Canada공시 • Jan 31BioSyent Inc. Declares First Quarter 2025 Dividend, Payable on March 14, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on March 14, 2025, to shareholders of record at the close of business on February 28, 2025. This first quarter 2025 dividend of $0.05 per common share represents an 11.1% increase from the fourth quarter 2024 dividend of $0.045 per common share.공시 • Nov 20December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.공시 • Nov 14BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024BioSyent Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 20, 2024공시 • Aug 27Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024BioSyent Inc. announced that its Board of Directors have declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share.공시 • May 18BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share.공시 • May 11BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024BioSyent Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on May 16, 2024공시 • Mar 19BioSyent Inc., Annual General Meeting, May 16, 2024BioSyent Inc., Annual General Meeting, May 16, 2024.공시 • Mar 07BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024BioSyent Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024공시 • Feb 07BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share.공시 • Nov 17BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share.공시 • Nov 10BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023BioSyent Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 16, 2023공시 • Aug 23BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. This third quarter 2023 dividend compares with the second quarter 2023 dividend of $0.04 per common share.공시 • Aug 16BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023BioSyent Inc. announced that they will report Q2, 2023 results After-Market on Aug 22, 2023공시 • May 26BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.공시 • May 19BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023BioSyent Inc. announced that they will report Q1, 2023 results at 8:00 AM, US Eastern Standard Time on May 26, 2023공시 • Feb 02BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend of $0.04 per common share.매출 및 비용 세부 내역BioSyent가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:BIOY.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2646923031 Dec 2543922030 Sep 2542921030 Jun 2540820031 Mar 2538820031 Dec 2435719030 Sep 2435719030 Jun 2434719031 Mar 2433718031 Dec 2332618030 Sep 2331618030 Jun 2329517031 Mar 2327516031 Dec 2228516030 Sep 2228615030 Jun 2228614031 Mar 2228614031 Dec 2129614030 Sep 2127514030 Jun 2126415031 Mar 2124413031 Dec 2022412030 Sep 2022411030 Jun 2023511031 Mar 2023511031 Dec 1921410030 Sep 1922510030 Jun 1921510031 Mar 1922610031 Dec 1822610030 Sep 1822510030 Jun 1822610031 Mar 1821510031 Dec 1721510030 Sep 172059030 Jun 171959031 Mar 171848031 Dec 161848030 Sep 161748030 Jun 161748031 Mar 161648031 Dec 151547030 Sep 151546030 Jun 1514460양질의 수익: BIOY.F는 고품질 수익을 보유하고 있습니다.이익 마진 증가: BIOY.F의 현재 순 이익률 (19.7%)은 지난해 (20.4%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BIOY.F의 수익은 지난 5년 동안 연평균 12.9% 증가했습니다.성장 가속화: 지난 1년간 BIOY.F 의 수익 증가율(15.5%)은 연간 평균(12.9%)을 초과합니다.수익 대 산업: BIOY.F의 지난 1년 수익 증가율(15.5%)은 Pharmaceuticals 업계의 -4.8%를 상회했습니다.자기자본이익률높은 ROE: BIOY.F의 자본 수익률(20.1%)은 높음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/29 22:37종가2026/05/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioSyent Inc.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tania Armstrong-WhitworthATB Cormark Historical (Cormark Securities)David MartinBloom Burton & Co.Scott CurtisCantor Fitzgerald Canada Corporation1명의 분석가 더 보기
공시 • May 08BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026
공시 • Mar 13BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026
공시 • Nov 14BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025
공시 • Aug 15BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025
공시 • May 09BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025
공시 • Mar 07BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025
공시 • May 21BioSyent Inc. Announces Health Canada Approval of Thyconvi (Levothyroxine Oral Solution)BioSyent Inc. announced that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (TSH) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi in Canada. Thyconvi is an oral liquid dosage containing 20 micrograms (mcg) of levothyroxine sodium per millilitre (mL). Thyconvi is indicated for: Hypothyroidism - as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis. Pituitary Thyrotropin (TSH) Suppression - as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. Thyconvi is supplied in a package of two 75 mL bottles without the need for refrigeration. Thyconvi offers broad, convenient dose flexibility for patients who have challenges taking solid doses.
공시 • May 16BioSyent Inc. Declares Second Quarter 2026 Dividend, Payable on June 15, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of CAD 0.055 per common share.
공시 • May 08BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026
공시 • Mar 13BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026
공시 • Mar 03BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc from a group of shareholders for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow, and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Rory Cattanach of Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc. BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million on February 8, 2026. A cash payment of CAD 22.5 million, of which CAD 0.2 million will be satisfied by granting 12,666 Restricted Share Units to certain Oral Science employees, vesting on the second anniversary of the grant date. Also issued 234,192 common shares valued at CAD 3.0 million, of which 167,635 are under a two-year escrow and 66,557 are under a two-year lock-up, releasing 25% every six months. An additional CAD 2 million cash was paid at closing for excess working capital. The sellers may also receive a contingent earn-out in 2027 based on 2025–2026 performance and royalties until 2033 of up to CAD 6 million.
공시 • Feb 17BioSyent Inc., Annual General Meeting, May 14, 2026BioSyent Inc., Annual General Meeting, May 14, 2026.
공시 • Feb 09BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc.
공시 • Jan 30BioSyent Inc. Declares Quarterly Dividend for the First Quarter of 2026, Payable on March 13, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share.
공시 • Nov 22BioSyent Declares Fourth Quarter 2025 Dividend, Payable on December 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share.
공시 • Nov 14BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025
공시 • Aug 22BioSyent Inc. Declares Dividend for Third Quarter of 2025, Payable on September 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.05 per common share, payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of CAD 0.05 per common share.
공시 • Aug 15BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025
공시 • May 16BioSyent Inc. Declares Second Quarter 2025 Dividend, Payable on June 13, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
공시 • May 09BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025
공시 • Mar 07BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025
공시 • Mar 05BioSyent Inc., Annual General Meeting, May 15, 2025BioSyent Inc., Annual General Meeting, May 15, 2025. Location: ontario, mississauga Canada
공시 • Jan 31BioSyent Inc. Declares First Quarter 2025 Dividend, Payable on March 14, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on March 14, 2025, to shareholders of record at the close of business on February 28, 2025. This first quarter 2025 dividend of $0.05 per common share represents an 11.1% increase from the fourth quarter 2024 dividend of $0.045 per common share.
공시 • Nov 20December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
공시 • Nov 14BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024BioSyent Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 20, 2024
공시 • Aug 27Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024BioSyent Inc. announced that its Board of Directors have declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share.
공시 • May 18BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share.
공시 • May 11BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024BioSyent Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on May 16, 2024
공시 • Mar 19BioSyent Inc., Annual General Meeting, May 16, 2024BioSyent Inc., Annual General Meeting, May 16, 2024.
공시 • Mar 07BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024BioSyent Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024
공시 • Feb 07BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share.
공시 • Nov 17BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share.
공시 • Nov 10BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023BioSyent Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 16, 2023
공시 • Aug 23BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. This third quarter 2023 dividend compares with the second quarter 2023 dividend of $0.04 per common share.
공시 • Aug 16BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023BioSyent Inc. announced that they will report Q2, 2023 results After-Market on Aug 22, 2023
공시 • May 26BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
공시 • May 19BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023BioSyent Inc. announced that they will report Q1, 2023 results at 8:00 AM, US Eastern Standard Time on May 26, 2023
공시 • Feb 02BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend of $0.04 per common share.